Compare PLRX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLRX | CRMD |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | 49 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.7M | 590.7M |
| IPO Year | 2020 | 2009 |
| Metric | PLRX | CRMD |
|---|---|---|
| Price | $1.08 | $7.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $2.67 | ★ $14.83 |
| AVG Volume (30 Days) | 360.5K | ★ 759.2K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.97 | ★ 780.00 |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.79 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $1.02 | $6.13 |
| 52 Week High | $1.95 | $13.02 |
| Indicator | PLRX | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 47.85 |
| Support Level | $1.02 | $7.09 |
| Resistance Level | $1.37 | $9.01 |
| Average True Range (ATR) | 0.05 | 0.23 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 9.09 | 32.10 |
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.